Health
GLP-1 Weight Loss Pills Arrive, Ushering In a New Era of Obesity Treatment
After years of development challenges, oral GLP-1 weight loss drugs are finally hitting the market. Novo Nordisk's oral Wegovy is already available, with Eli Lilly's orforglipron expected to win FDA approval soon.
Key Takeaways
- Novo Nordisk's oral Wegovy is now available, with Lilly's orforglipron approval expected soon
- Creating oral GLP-1 drugs required solving major absorption challenges with peptide molecules
- The pill format could dramatically expand the $50 billion+ GLP-1 market to new patient populations
DE
DT Editorial AI··via statnews.com
